Sort   by:  
 Page size 
ProteomicsABPP of Ibrutinib Resistance in B Cell Malignancies
Ibrutinib,a novel Bruton'styrosine kinase inhibitor, demonstrated high response rates in B-cell lymphomas but a growing number of ibrutinib treated patients relapse with resistance, fulminant progression and accelerated mortality. Using chemical proteomics and a high-throughput ex vivo assay in a re...
ORGANISM(S): Homo sapiens (Human) 
2018-10-26 | PXD005734 | Pride
Ibrutinib Activity-based protein profiling B-cell cancers Lc-ms/ms 
GenomicsEGR1-mediated ibrutinib resistance
EGR1-mediated ibrutinib resistance
PRJNA925145 | ENA
TranscriptomicsTargeting of ibrutinib resistance–driving pathways by miR-28 in ABC-DLBCL
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive B-cell lymphoma. Although many patients respond well to R-CHOP immunochemotherapy, those with the activated B-cell (ABC) subtype are often refractory or relapse. Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib have improve...
ORGANISM(S): Homo sapiens 
2026-03-10 | E-MTAB-16241 | biostudies-arrayexpress
ProteomicsThe conformational state of PLCγ cSH2-linker contributes to Ibrutinib resistance
Mutations in PLCγ, a substrate of the tyrosine kinase BTK, are often found in patients who develop resistance to the BTK inhibitor Ibrutinib. However, the mechanisms by which these PLCγ mutations cause Ibrutinib resistance are unclear. Under normal signaling conditions, BTK mediated phosphorylation ...
ORGANISM(S): Rattus norvegicus (Rat) 
2022-01-19 | PXD028923 | Pride
Plcγ  phospholipase c gamma  ibrutinib resistance  allostery  hdx-ms  hydrogen/deuterium exchange mass spectrometry  nmr  sh2 domain. 
Genomicsibrutinib resistance mantle cell lymphoma [Pt_RNA]
ibrutinib resistance mantle cell lymphoma [Pt_RNA]
PRJNA593340 | ENA
Genomicsibrutinib resistance mantle cell lymphoma [ChIP-seq]
ibrutinib resistance mantle cell lymphoma [ChIP-seq]
PRJNA593341 | ENA
Genomicsibrutinib resistance mantle cell lymphoma [RNA-seq]
ibrutinib resistance mantle cell lymphoma [RNA-seq]
PRJNA593342 | ENA
ProteomicsLongitudinal omics data and preclinical treatment identify proteasome inhibition as therapy for ibrutinib-resistant CLL
Chronic lymphocytic leukemia (CLL) is a malignant lymphoproliferative disorder characterized by the accumulation of small mature B cells in blood and secondary lymphoid tissues. Novel drugs, such as the Bruton tyrosine kinase (BTK) inhibitor ibrutinib, have greatly improved survival of CLL patients,...
ORGANISM(S): Homo sapiens (Human) Mus musculus (Mouse) 
2024-12-10 | PXD053512 | Pride
Cll Btki Carfilzomib Proteasome Quantitative proteomics Transcriptomics Ibrutinib-resistance 
ProteomicsMetabolomics Integration with Gene expression profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC large B cell Lymphoma
Drug resistant acute B-cell lymphoma cells were analyzed via LC-MS metabolomics to identify deregulated metabolic pathways that are associated with drug resistance.
ORGANISM(S): Human 
2021-03-16 | MSV000087059 | MassIVE
TranscriptomicsChromatin structure analysis for two patients on Ibrutinib and showing disease progression in chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in developed countries. Ibrutinib (PCI-32765), a specific and irreversible inhibitor of Bruton's Tyrosine Kinase (BTK) represents a major step forward in the treatment of CLL, but cases of resistance are emerging. We ha...
ORGANISM(S): Homo sapiens 
2020-09-01 | E-MTAB-8220 | biostudies-arrayexpress
Sort   by:  
 Page size